Supplementary Tables S1-S7 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes

Supplementary Table S1. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Discovery cohort. Supplementary Table S2. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Validation cohort. Supplementary Table S3. Summary of mutations detected by plasma-based targeted sequencing panel. Supplementary Table S4. Correlation of TF expression between GBM and other tumor types. Supplementary Table S5. Summary of complete blood count for patients with gliomas or non-neoplastic neurological conditions. Supplementary Table S6. Summary of ChIP-Seq peaks used in DECIFER analysis. Supplementary Table S7. Correlation of TFBS relative coverage differences with expression differences between tumor/cell types and whole blood.补充表S1：发现队列中循环游离DNA（cell-free DNA, cfDNA）分析的临床信息、测序统计数据及ARTEMIS-DELFI评分。补充表S2：验证队列中循环游离DNA分析的临床信息、测序统计数据及ARTEMIS-DELFI评分。补充表S3：基于血浆的靶向测序panel（targeted sequencing panel）所检测到的突变汇总。补充表S4：胶质母细胞瘤（Glioblastoma Multiforme, GBM）与其他肿瘤类型之间转录因子（Transcription Factor, TF）表达的相关性。补充表S5：神经胶质瘤患者或非肿瘤性神经系统疾病患者的全血细胞计数（complete blood count）汇总。补充表S6：DECIFER分析中使用的染色质免疫共沉淀测序（Chromatin Immunoprecipitation Sequencing, ChIP-Seq）峰汇总。补充表S7：肿瘤/细胞类型与全血之间的转录因子结合位点（Transcription Factor Binding Site, TFBS）相对覆盖度差异与表达差异的相关性。